Does Centene Corporation Cover Forteo?

How Centene Corporation Structures Forteo Coverage

Centene is the largest Medicaid managed care organization in the United States, operating plans in more than 30 states under subsidiaries like Ambetter, WellCare, Peach State Health Plan, Sunshine Health, and others [1]. Because each subsidiary files its own formulary with state or federal regulators, Forteo coverage details differ by plan type and geography.

Formulary Tier Placement

Across most Centene formularies reviewed for 2025 and 2026 plan years, Forteo sits on the specialty tier (typically Tier 4 or Tier 5). Specialty tier placement means the drug requires dispensing through a designated specialty pharmacy, and cost-sharing is calculated as coinsurance (a percentage of the drug's cost) rather than a flat copay [2].

Medicaid vs. Medicare Advantage vs. Marketplace

Centene's Medicaid managed care plans must cover all FDA-approved drugs that the manufacturer participates in the Medicaid Drug Rebate Program for, per the Omnibus Budget Reconciliation Act of 1990. Eli Lilly participates in this program, so state Medicaid MCOs operated by Centene cannot exclude Forteo outright [3]. They can, however, impose prior authorization and preferred drug list requirements.

WellCare Medicare Advantage plans follow CMS Part D formulary rules. CMS requires that Part D sponsors cover "all or substantially all" drugs in certain protected classes, but osteoporosis agents are not a protected class. WellCare can therefore restrict Forteo to non-preferred specialty status and mandate step therapy [4].

Ambetter marketplace plans set their own formularies within ACA essential health benefit requirements. Forteo appears on most Ambetter formularies but with quantity limits (one pen per 28 days) and mandatory prior authorization.

Prior Authorization Requirements for Forteo Under Centene Plans

Getting Forteo approved through a Centene plan is not automatic. The prior authorization process serves as the primary gatekeeper, and denials are common when documentation is incomplete.

What Centene Typically Requires

Based on publicly available Centene subsidiary formulary criteria, prior authorization for Forteo generally demands:

• A confirmed diagnosis of osteoporosis, documented by dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the hip or spine, or a history of fragility fracture [5].
• Failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate or risedronate are the most commonly required first-line agents). The Endocrine Society's 2020 clinical practice guideline supports bisphosphonates as first-line therapy for most patients, reserving teriparatide for those at very high fracture risk [6].
• Prescriber attestation that the patient has not previously completed a full 24-month course of teriparatide (the FDA-labeled maximum duration, based on the finding of osteosarcoma in rats exposed to high-dose teriparatide for near-lifetime durations) [7].
• Clinical notes supporting high fracture risk. The FRAX score, while not universally mandated, strengthens the authorization request. A 10-year major osteoporotic fracture probability exceeding 20% or hip fracture probability exceeding 3% aligns with the National Osteoporosis Foundation's intervention thresholds [8].

Timeline and Urgent Exceptions

Standard prior authorization decisions from Centene subsidiaries follow state-specific timelines, but CMS mandates a 72-hour standard decision window and a 24-hour expedited window for Medicare Advantage and Part D plans [4]. Medicaid MCO timelines vary by state. In practice, many authorizations process within 5 to 10 business days for Medicaid plans.

If the prescriber documents that delay would seriously jeopardize the patient's health (for example, a patient with recent vertebral fracture and ongoing fracture cascade risk), the plan must process an expedited review.

Step Therapy: What You Must Try Before Forteo

Step therapy is the most frequent barrier Centene members face when seeking Forteo coverage. The logic is straightforward from the payer's perspective: oral bisphosphonates cost a fraction of Forteo's price and carry strong evidence for fracture reduction.

First-Line Bisphosphonate Evidence

The Fracture Intervention Trial (FIT) demonstrated that alendronate 10 mg daily reduced vertebral fractures by 47% over three years in women with existing vertebral fractures (N=2,027) [9]. Risedronate showed similar efficacy in the VERT trial, reducing new vertebral fractures by 41% over three years (N=2,458) [10].

When Forteo Becomes Appropriate

Teriparatide is an anabolic agent. It builds new bone rather than simply slowing resorption. The key Neer et al. Trial (N=1,637) showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fractures by 53% compared to placebo over a median of 21 months [11]. The VERO trial (N=1,360) later demonstrated teriparatide's superiority over risedronate, with 56% lower risk of new vertebral fractures over 24 months [12].

These data support positioning teriparatide after bisphosphonate failure or as initial therapy in patients with very high fracture risk, defined by the Endocrine Society as those with a recent fracture (within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, or a T-score below -3.0 [6].

To satisfy Centene's step therapy, document the bisphosphonate trial dates, duration, reason for discontinuation, and any adverse events (esophageal irritation, musculoskeletal pain, atypical femur fracture concern) in the clinical notes submitted with the prior authorization.

Out-of-Pocket Costs for Forteo on Centene Plans

The financial burden of Forteo varies enormously depending on the specific Centene subsidiary and benefit design.

Medicaid Plans

Centene's Medicaid members typically face low or zero out-of-pocket costs for covered specialty drugs, as most state Medicaid programs cap monthly copays at $3 to $4 for preferred brands. Some states impose no copay for injectable medications dispensed through specialty pharmacy. This makes Forteo more accessible for Medicaid-eligible patients than for those on commercial or Medicare plans [3].

Medicare Advantage (WellCare)

WellCare Part D plans place Forteo on the specialty tier, where coinsurance commonly runs 25% to 33% of the negotiated price. At an approximate cost of $4,100 per pen, this translates to roughly $1,025 to $1,353 per month before any manufacturer assistance. The Medicare Part D catastrophic coverage phase kicks in after the member reaches $8,000 in true out-of-pocket spending (2025 threshold per the Inflation Reduction Act's $2,000 annual cap provision, fully effective in 2025), which significantly limits annual exposure [13].

Under the Inflation Reduction Act's Part D redesign, annual out-of-pocket costs for Part D drugs are capped at $2,000 starting in 2025, which meaningfully reduces the cost burden for Forteo users on WellCare Medicare plans [13].

Marketplace (Ambetter)

Ambetter plans typically apply specialty coinsurance of 20% to 40% after deductible. Annual out-of-pocket maximums for ACA marketplace plans ($9,200 for individual coverage in 2025) provide an upper bound, but members using Forteo alongside other medications may reach that maximum within a few months [14].

How to Appeal a Forteo Denial From Centene

Denials happen. A 2021 analysis published in JAMA Internal Medicine found that insurers denied roughly 18% of in-network prior authorization requests across all drug classes [15]. Osteoporosis medications with high acquisition costs face higher-than-average denial rates.

Internal Appeal Steps

File a written internal appeal within 60 days of the denial notice (180 days for Medicare Advantage plans). Include:

• A letter of medical necessity from the prescribing physician, referencing the patient's DXA scores, fracture history, and FRAX results.
• Documentation of bisphosphonate failure or intolerance, with dates and clinical details.
• Supporting guideline citations. The Endocrine Society guideline (2020), the American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guideline, and the VERO trial results are particularly useful references [6][12][16].

External Review

If the internal appeal fails, every Centene plan type offers an external review pathway. For marketplace plans, the ACA guarantees independent external review. For Medicare Advantage, CMS provides a multi-level appeals process culminating in Administrative Law Judge review for claims exceeding $180 (2025 threshold) [4].

Peer-to-peer review, where the prescribing physician speaks directly with the plan's medical director, often resolves denials faster than written appeals alone. Request this option explicitly.

Alternatives to Forteo Covered by Centene

If Forteo is denied or cost-prohibitive, several alternatives exist within Centene formularies.

Other Anabolic or Dual-Action Agents

Abaloparatide (Tymlos), a parathyroid hormone-related peptide analog, is FDA-approved for postmenopausal osteoporosis. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% versus placebo over 18 months [17]. Some Centene formularies list Tymlos as a covered alternative, though it carries similar prior authorization requirements and specialty tier placement.

Romosozumab (Evenity), a sclerostin inhibitor, received FDA approval in 2019. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone over 24 months [18]. Romosozumab carries a black box warning for cardiovascular risk, limiting its use in patients with recent myocardial infarction or stroke.

Bisphosphonate Options

Zoledronic acid (Reclast), given as a once-yearly intravenous infusion, offers an alternative for patients who cannot tolerate oral bisphosphonates. The HORIZON-PFT trial (N=7,765) showed zoledronic acid reduced vertebral fractures by 70% and hip fractures by 41% over three years [19]. Most Centene plans cover zoledronic acid infusion as a medical benefit (not pharmacy benefit), which can reduce out-of-pocket costs.

Denosumab (Prolia), a RANKL inhibitor given as a subcutaneous injection every six months, is another option. The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures over three years [20]. Denosumab sits on most Centene formularies at a lower tier than Forteo, making it a frequently preferred alternative from the payer's perspective.

Forteo Patient Assistance and Copay Programs

Eli Lilly operates the Lilly Cares Foundation patient assistance program for uninsured or underinsured patients. Eligibility requires income at or below 400% of the federal poverty level and no prescription drug coverage for Forteo [21].

For commercially insured patients (including those on Ambetter marketplace plans), Eli Lilly offers the Forteo Savings Card, which can reduce monthly copays to as low as $4 for eligible patients. This card does not apply to government-funded insurance (Medicaid, Medicare, TRICARE) due to federal anti-kickback statute restrictions.

Specialty pharmacies contracted with Centene subsidiaries may also offer financial counseling. Ask the dispensing pharmacy about manufacturer copay assistance, foundation grants (such as those from the HealthWell Foundation or the Patient Access Network Foundation), and payment plans.

Requesting a Formulary Exception From Centene

When standard appeals fail, a formulary exception request provides another pathway. This asks the plan to cover Forteo at a lower cost-sharing tier or to waive step therapy requirements entirely.

Grounds for Exception

Under CMS rules for Medicare Advantage and Part D, a formulary exception must be granted if the prescriber demonstrates that the formulary alternatives would not be as effective for the patient or would cause adverse effects [4]. ACA marketplace rules contain similar protections.

Document the specific clinical reason each formulary alternative is inappropriate. For example: "Patient developed osteonecrosis of the jaw after three years of alendronate" or "Patient sustained two new vertebral fractures while adherent to denosumab for 24 months."

Processing Time

Exception requests follow the same timeline as prior authorizations (72 hours standard, 24 hours expedited for Medicare plans). The plan must provide written notice of the decision, including appeal rights if denied.

A 2023 report from the Office of Inspector General found that Medicare Advantage organizations overturned 75% of prior authorization denials on appeal, suggesting that persistence pays off for patients and prescribers navigating these systems [22].